Isofol Medical AB (publ)

OM:ISOFOL Stock Report

Market Cap: SEK 169.6m

Isofol Medical Future Growth

Future criteria checks 0/6

Isofol Medical is forecast to grow earnings and revenue by 38.1% and 107.7% per annum respectively. EPS is expected to grow by 13.7% per annum. Return on equity is forecast to be -41% in 3 years.

Key information

38.1%

Earnings growth rate

13.74%

EPS growth rate

Biotechs earnings growth24.9%
Revenue growth rate107.7%
Future return on equity-40.96%
Analyst coverage

Low

Last updated17 Jun 2025

Recent future growth updates

Recent updates

We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow

Jul 12
We're Interested To See How Isofol Medical (STO:ISOFOL) Uses Its Cash Hoard To Grow

An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued

May 18
An Intrinsic Calculation For Isofol Medical AB (publ) (STO:ISOFOL) Suggests It's 45% Undervalued

Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation

Nov 09
Here's Why We're Not At All Concerned With Isofol Medical's (STO:ISOFOL) Cash Burn Situation

Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?

May 12
Is Isofol Medical (STO:ISOFOL) In A Good Position To Deliver On Growth Plans?

Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)

Apr 08
Market Sentiment Around Loss-Making Isofol Medical AB (publ) (STO:ISOFOL)

Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment

Mar 03
Isofol Medical (STO:ISOFOL) Has Gifted Shareholders With A Fantastic 127% Total Return On Their Investment

We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully

Jan 10
We Think Isofol Medical (STO:ISOFOL) Needs To Drive Business Growth Carefully

Earnings and Revenue Growth Forecasts

OM:ISOFOL - Analysts future estimates and past financials data (SEK Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/2027N/A-59-59-591
12/31/2026N/A-67-67-671
12/31/2025N/A-60-60-601
3/31/2025N/A-49-45-45N/A
12/31/2024N/A-43-42-42N/A
9/30/2024N/A-39-40-40N/A
6/30/20240-35-39-39N/A
3/31/20240-35-46-46N/A
12/31/20231-37-53-53N/A
9/30/20233-54-91-91N/A
6/30/20235-80-120-120N/A
3/31/20239-120-155-155N/A
12/31/202213-160-193-193N/A
9/30/202216-196-190-190N/A
6/30/202218-214-209-209N/A
3/31/202221-209-201-201N/A
12/31/202122-200-188-188N/A
9/30/202136-194-182-182N/A
6/30/202150-173-148-148N/A
3/31/202142-176-142-142N/A
12/31/202037-189-160-160N/A
9/30/202018-192-186-186N/A
6/30/2020N/A-204-183-183N/A
3/31/2020N/A-191-176-176N/A
12/31/2019N/A-162-148-147N/A
9/30/2019N/A-133-106-105N/A
6/30/2019N/A-108-101-101N/A
3/31/2019N/A-90-96-96N/A
12/31/2018N/A-83N/A-92N/A
9/30/20180-80N/A-90N/A
6/30/20180-82N/A-86N/A
3/31/20180-79N/A-73N/A
12/31/20170-72N/A-62N/A
9/30/20170-77N/A-57N/A
6/30/20170-66N/A-47N/A
3/31/20170-63N/A-46N/A
12/31/20161-65N/A-47N/A
12/31/20150-41N/A-37N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: ISOFOL is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ISOFOL is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ISOFOL is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ISOFOL is forecast to have no revenue next year.

High Growth Revenue: ISOFOL is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: ISOFOL is forecast to be unprofitable in 3 years.

Discover growth companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/07/23 02:11
End of Day Share Price 2025/07/23 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Isofol Medical AB (publ) is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ulrik TrattnerCarnegie Investment Bank AB
Ole-Andreas KrohnDNB Carnegie
David MartinssonDNB Carnegie